Vaborbactam
Vaborbactam is a beta-lactamase inhibitor used in combination with the antibiotic meropenem to treat certain serious bacterial infections. It is particularly effective against carbapenem-resistant Enterobacteriaceae (CRE), which are a significant cause of hospital-acquired infections.
Mechanism of Action[edit | edit source]
Vaborbactam works by inhibiting the activity of beta-lactamase enzymes produced by bacteria. These enzymes typically break down beta-lactam antibiotics, rendering them ineffective. By inhibiting these enzymes, vaborbactam allows meropenem to retain its antibacterial activity against resistant strains.
Clinical Use[edit | edit source]
Vaborbactam is used in combination with meropenem for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, and for the treatment of complicated intra-abdominal infections (cIAIs). It is also used for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
Pharmacokinetics[edit | edit source]
Vaborbactam is administered intravenously and has a half-life that allows for dosing every 8 hours when combined with meropenem. It is primarily excreted unchanged in the urine.
Side Effects[edit | edit source]
Common side effects of vaborbactam include headache, nausea, diarrhea, and infusion site reactions. Serious side effects may include allergic reactions and seizures.
Approval and Availability[edit | edit source]
Vaborbactam was approved by the Food and Drug Administration (FDA) in 2017 for use in combination with meropenem. It is marketed under the brand name Vabomere.
See Also[edit | edit source]
- Beta-lactamase inhibitor
- Meropenem
- Carbapenem-resistant Enterobacteriaceae
- Hospital-acquired infection
- Urinary tract infection
- Intra-abdominal infection
- Pneumonia
References[edit | edit source]
External Links[edit | edit source]
| Vaborbactam | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Intravenous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
